Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Funding

Mogrify Raises $3.7 Million USD Seed Funding to Accelerate Its Mission to Transform Cell Therapy via Direct Cellular Conversion


Cell Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, today announced a second close on its seed funding, bringing the total raised to $3.7 million USD, and the appointment of Darrin M Disley, PhD, DSc, OBE, as CEO. The Company will use the funding to market novel IP and cell types generated using its proprietary direct cellular conversion platform, which will power the development and manufacture of lifesaving cell therapies across all therapeutic areas. The funding round was led by existing investor Ahren Innovation Capital (Ahren), with 24Haymarket and Dr Disley also investing.

Mogrify builds on a 10 year investment by its co-founders in the development of a systematic big data-science approach (Rackham et al., Nature Genetics, 2016) powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo), needed to convert any mature cell type into any other mature cell type without going through a pluripotent stem cell- or even a progenitor cell-state. The Company is applying this approach to address the issues of efficacy, safety and scalability currently associated with cell therapy development and manufacturing, which is estimated to represent a $30 billion USD market opportunity and is rapidly growing (CAGR +30%). Further, through its internal development and partnership programs, the Company is positioned to directly address growing markets that are unserved by approved cell therapies, such as cardiac repair and cartilage regeneration end-user markets, estimated to be worth $120 billion USD and $7 billion USD by 2022 and 2025, respectively.

Mogrify's leadership team is of significant commercial and scientific caliber. The Company was founded by leading academics in bioinformatics, Professor Julian Gough (LMB, Cambridge, UK), cell reprograming, Professor Jose Polo (Monash University, Melbourne, AU), and machine learning, Assistant Professor Owen Rackham (Duke-NUS, Singapore), and is chaired by Professor Steve Jackson, FRS, Ahren Science Partner, originator of Olaparib/Lynparza, and University of Cambridge Professor of Biology.

Dr Disley is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown or invested in over 40 start-up life science, technology and social enterprises, raising $500 million USD in business financing and closing $600 million USD in commercial deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the Company from start-up through a $113 million USD IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and gene modulation technologies. He was appointed OBE in 2018 for his services to business and enterprise in the healthcare sector.

Professor Julian Gough, PhD, Co-founder and CSO, Mogrify, said: "To have the backing of such high-profile investors at this stage in the Company's development is testament to the strength of both the Mogrify technology and the promised growth potential offered by a highly scalable business model. I look forward to working with Darrin as CEO. I believe we have a shared mission to transform the future development of lifesaving cell therapies."

Dr Darrin M Disley, OBE, CEO, Mogrify, said: "Direct reprograming between mature human cell types is a holy grail of regenerative medicine and pharmaceutical applications. We will commercialize the Mogrify cellular trans differentiation platform via IP licensing, product development, internal and partnered drug development. I am thrilled to be working with a world-class multi-disciplinary founding team, and a lead investor with founders of rarely matched scientific pedigree, as we rapidly expand to address the global cell therapy opportunity."

Alice Newcombe-Ellis, Founder and Managing Partner, Ahren Innovation Capital, said: "Mogrify's team has a strong track record of success, and their cutting-edge approach to direct cellular conversion has the potential to disrupt cell therapy, placing the Company in a unique position to address a large market opportunity. This is an exciting time for Mogrify and we are pleased to be supporting them."

Rackham OJL et al. A predictive computational framework for direct reprogramming between human cell types. Nature Genetics. 2016 Mar;48(3):331-5. doi: 10.1038/ng.3487. Epub 2016 Jan 18.

ENDS

For further information please visit www.mogrify.co.uk


These press releases may also interest you

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....

at 10:00
Driving is the leading cause of work-related death each year in the United States, with nearly 40% of deaths on the job occurring on American roads according to the U.S. Bureau of Labor Statistics. A major contributing factor to road deaths each...

at 10:00
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according...

at 10:00
NastLaw LLC announces: If you purchased certain named generic pharmaceutical drugs directly from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019, your rights may be affected by proposed class action settlements.A...

at 09:48
Perspire Sauna Studio, one of the country's largest sauna franchises specializing in full spectrum infrared (IR) and red-light therapy (RLT), is rolling out a new sauna design and member experience through the brand's long-standing partnership with...



News published on and distributed by: